News | 29 November 2021
Bharat Biotech commences export of Covaxin
It’s a two-dose vaccine administered 28 days apart
It’s a two-dose vaccine administered 28 days apart
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues
One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
Officials from ACG signed the MoU with the Maharashtra government for the Rs 600 crore investment in the backward region of Marathwada
For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
This is a shot in the arm for the vaccine manufacturers
Betting big on talent, resources, and the ecosystem required for innovation and enterprise, Prime Minister Narendra Modi invited stakeholders to ideate in India, innovate in India and Make in India for the world
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Subscribe To Our Newsletter & Stay Updated
